EGFR and metastatic neoplasm: Antiepidermal growth factor (EGFR) agents such as cetuximab or erlotinib would be another approach to consider as radiosensitizing agents, because preliminary reports have suggested that the EGFR pathway may play an important role in the normal physiology of the cutaneous epidermis, [15] and potentially in NMSC metastatic disease [34, 35].